Logo image of CSCI.CA

COSCIENS BIOPHARMA INC (CSCI.CA) Stock Fundamental Analysis

TSX:CSCI - Toronto Stock Exchange - CA22112H1010 - Common Stock - Currency: CAD

3.95  -0.05 (-1.25%)

Fundamental Rating

2

Overall CSCI gets a fundamental rating of 2 out of 10. We evaluated CSCI against 23 industry peers in the Biotechnology industry. While CSCI seems to be doing ok healthwise, there are quite some concerns on its profitability. CSCI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CSCI had negative earnings in the past year.
In the past year CSCI has reported a negative cash flow from operations.
CSCI had negative earnings in each of the past 5 years.
In the past 5 years CSCI always reported negative operating cash flow.
CSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFCSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M -50M

1.2 Ratios

CSCI has a better Return On Assets (-32.47%) than 70.83% of its industry peers.
CSCI's Return On Equity of -71.02% is amongst the best of the industry. CSCI outperforms 83.33% of its industry peers.
Industry RankSector Rank
ROA -32.47%
ROE -71.02%
ROIC N/A
ROA(3y)-31.91%
ROA(5y)-27.9%
ROE(3y)-56.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSCI.CA Yearly ROA, ROE, ROICCSCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400

1.3 Margins

The Gross Margin of CSCI (43.00%) is better than 75.00% of its industry peers.
In the last couple of years the Gross Margin of CSCI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CSCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y39.35%
GM growth 5Y0.62%
CSCI.CA Yearly Profit, Operating, Gross MarginsCSCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSCI has less shares outstanding than it did 1 year ago.
CSCI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CSCI is higher compared to a year ago.
CSCI.CA Yearly Shares OutstandingCSCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
CSCI.CA Yearly Total Debt VS Total AssetsCSCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.47, we must say that CSCI is in the distress zone and has some risk of bankruptcy.
With an excellent Altman-Z score value of -0.47, CSCI belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
CSCI has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.06, CSCI is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -0.47
ROIC/WACCN/A
WACC8.15%
CSCI.CA Yearly LT Debt VS Equity VS FCFCSCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

CSCI has a Current Ratio of 3.46. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.46, CSCI is doing good in the industry, outperforming 75.00% of the companies in the same industry.
CSCI has a Quick Ratio of 3.05. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
CSCI has a Quick ratio of 3.05. This is in the better half of the industry: CSCI outperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.05
CSCI.CA Yearly Current Assets VS Current LiabilitesCSCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

CSCI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -274.15%.
Looking at the last year, CSCI shows a decrease in Revenue. The Revenue has decreased by -7.05% in the last year.
Measured over the past years, CSCI shows a very negative growth in Revenue. The Revenue has been decreasing by -30.07% on average per year.
EPS 1Y (TTM)-274.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.95%
Revenue 1Y (TTM)-7.05%
Revenue growth 3Y6.73%
Revenue growth 5Y-30.07%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.75%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.27%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CSCI.CA Yearly Revenue VS EstimatesCSCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CSCI.CA Yearly EPS VS EstimatesCSCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CSCI. In the last year negative earnings were reported.
Also next year CSCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSCI.CA Price Earnings VS Forward Price EarningsCSCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSCI.CA Per share dataCSCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CSCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COSCIENS BIOPHARMA INC

TSX:CSCI (3/7/2025, 7:00:00 PM)

3.95

-0.05 (-1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners7.38%
Inst Owner ChangeN/A
Ins Owners1.24%
Ins Owner ChangeN/A
Market Cap14.93M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)87.52%
Min Revenue beat(2)66.76%
Max Revenue beat(2)108.29%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.63
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-15.77
EYN/A
EPS(NY)-4.93
Fwd EYN/A
FCF(TTM)-6.75
FCFYN/A
OCF(TTM)-6.43
OCFYN/A
SpS2.42
BVpS7.59
TBVpS6.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.47%
ROE -71.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43%
FCFM N/A
ROA(3y)-31.91%
ROA(5y)-27.9%
ROE(3y)-56.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y39.35%
GM growth 5Y0.62%
F-Score1
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.66%
Cap/Sales 13.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.05
Altman-Z -0.47
F-Score1
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)148.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.23%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-274.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.95%
EPS Next Y68.75%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.05%
Revenue growth 3Y6.73%
Revenue growth 5Y-30.07%
Sales Q2Q%N/A
Revenue Next Year-2.27%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.76%
OCF growth 3YN/A
OCF growth 5YN/A